Last updated: September 21, 2026
Ferric citrate is a mature, commercially established phosphate binder and oral iron product with a concentrated market structure. In the United States, Akebia Therapeutics’ Auryxia is the principal ferric citrate product. Auryxia generated roughly $168 million in U.S. net product revenue in 2022 and approximately $178 million in 2023, according to Akebia’s annual filings. Growth has been steady but limited by dialysis-market concentration, generic substitution risk, competing phosphate binders, and the commercial transition toward Akebia’s newer anemia drug, Vafseo.[1]
The product’s strongest commercial position is its dual indication: hyperphosphatemia in adults with chronic kidney disease on dialysis and iron-deficiency anemia in adults with chronic kidney disease not on dialysis. Its market is substantially smaller than the overall phosphate-binder market because calcium-based binders, sevelamer, lanthanum carbonate, and sucroferric oxyhydroxide remain entrenched alternatives.
What is ferric citrate and which pharmaceutical products contain it?
Ferric citrate is an oral iron-based phosphate binder. In the gastrointestinal tract, ferric iron binds dietary phosphate and forms insoluble complexes that reduce phosphate absorption. A portion of the iron is absorbed and can contribute to iron replacement.
| Product |
Active ingredient |
Manufacturer or commercial sponsor |
Primary market |
Regulatory status |
| Auryxia |
Ferric citrate coordination complex |
Akebia Therapeutics |
United States |
FDA approved |
| Riona |
Ferric citrate hydrate |
Japan Tobacco and Torii Pharmaceutical |
Japan |
Approved in Japan |
| Triferic |
Ferric pyrophosphate citrate |
Rockwell Medical |
Dialysis iron replacement |
Different active ingredient |
| Vafseo |
Vadadustat |
Akebia Therapeutics |
Anemia of CKD |
Not ferric citrate |
Auryxia is available as 210 mg ferric iron tablets. The product’s commercial value comes from combining phosphate binding with iron delivery, which can reduce the need for separate intravenous or oral iron treatment in selected patients.
What FDA approvals does Auryxia have?
The FDA approved Auryxia in 2014 for controlling serum phosphorus levels in adults with chronic kidney disease on dialysis. The FDA later expanded the label in 2020 to include treatment of iron-deficiency anemia in adults with chronic kidney disease not on dialysis.[2]
The two indications create different commercial dynamics:
- The dialysis indication is driven by nephrologists, dialysis organizations, formulary contracts, and phosphate-control protocols.
- The non-dialysis anemia indication competes with oral iron, intravenous iron, erythropoiesis-stimulating agents, and newer hypoxia-inducible factor prolyl hydroxylase inhibitors.
- The product is not approved as a general-purpose iron supplement or for anemia unrelated to chronic kidney disease.
Auryxia’s regulatory profile is therefore broader than that of a conventional phosphate binder but narrower than that of a general oral iron product.
How has ferric citrate revenue changed over time?
Auryxia revenue has followed a moderate-growth trajectory rather than a high-growth specialty-pharmaceutical pattern.
| Fiscal year |
Approximate Auryxia net product revenue |
Commercial interpretation |
| 2020 |
About $117 million |
Early expansion after the anemia indication |
| 2021 |
About $156 million |
Increased adoption in CKD not on dialysis |
| 2022 |
About $168 million |
Continued growth with dialysis concentration |
| 2023 |
About $178 million |
Mature-product expansion and pricing support |
Figures are rounded from Akebia’s SEC filings and company disclosures.[1] Reported revenue may differ from gross sales because of rebates, chargebacks, discounts, patient-support programs, and other deductions.
The principal drivers of the revenue increase were:
- Greater use in non-dialysis chronic kidney disease.
- Continued prescriptions for dialysis-associated hyperphosphatemia.
- Retention of patients who benefit from simultaneous phosphate binding and iron replacement.
- Contracting and commercial execution by Akebia after its acquisition of Keryx Biopharmaceuticals.
The principal constraints were payer controls, product tolerability, pill burden, competing phosphate binders, and the maturity of the U.S. dialysis market.
How does ferric citrate compare with competing phosphate binders?
Ferric citrate competes mainly with sevelamer, sucroferric oxyhydroxide, calcium acetate, lanthanum carbonate, and other phosphate-control products.
| Product class |
Key advantage |
Key limitation |
Competitive position |
| Ferric citrate |
Phosphate binding plus iron delivery |
Gastrointestinal effects, pill burden, cost |
Differentiated niche |
| Sevelamer |
Broad clinical use and extensive experience |
High pill burden and gastrointestinal tolerability issues |
Major incumbent |
| Sucroferric oxyhydroxide |
Lower pill burden in some patients |
Cost and gastrointestinal adverse effects |
Strong branded competitor |
| Calcium acetate |
Low acquisition cost |
Hypercalcemia and vascular-calcification concerns |
Important low-cost option |
| Lanthanum carbonate |
Effective phosphate reduction |
Chewable administration and cost |
Established alternative |
Auryxia’s commercial argument is strongest when physicians value iron delivery as part of phosphate-management treatment. The argument is weaker when payers prioritize acquisition cost or when patients require a low-pill-burden regimen.
What patents protect ferric citrate and Auryxia?
Auryxia’s U.S. patent estate has historically included composition, formulation, and method-of-use claims. The commercially relevant protection has focused on:
- Ferric citrate compositions used as phosphate binders.
- Pharmaceutical tablets containing ferric citrate.
- Treatment of hyperphosphatemia in chronic kidney disease.
- Treatment of iron-deficiency anemia in chronic kidney disease not on dialysis.
- Dosing and administration methods.
Key early U.S. patent protection included U.S. Patent No. 7,767,851, which covered aspects of ferric citrate phosphate-binding technology. Later patents and regulatory exclusivities extended protection for particular indications and commercial uses. The precise enforceability of each patent depends on claim scope, terminal disclaimers, patent-term adjustment, and litigation outcomes. The FDA Orange Book remains the controlling source for active listed patents and expiration information.[3]
The patent estate is narrower than the product’s full commercial franchise. A generic may avoid one method-of-use patent by using a skinny label, while still creating practical substitution pressure through pharmacy-level dispensing, payer formularies, or off-label use.
When does ferric citrate lose exclusivity?
Ferric citrate has already lost the practical benefit of new chemical entity exclusivity in the United States. The original FDA approval occurred in 2014, and the five-year NCE period is no longer a barrier to abbreviated new drug applications.
The remaining barriers are patent-based and commercial:
| Protection type |
Status |
| FDA NCE exclusivity |
Expired |
| Pediatric exclusivity |
No longer a primary barrier |
| Product patents |
Expiration varies by patent and legal status |
| Method-of-use patents |
Can remain relevant after composition protection |
| Formulation patents |
May restrict specific tablet or dosage-form approaches |
| ANDA litigation |
Determines launch timing for individual generic sponsors |
Generic entry risk is therefore determined by the Orange Book patent list, Paragraph IV certifications, settlement agreements, and the ability of generic manufacturers to design around method-of-use claims.
Which companies are challenging Auryxia patents?
Generic-drug companies have pursued or evaluated Auryxia through the ANDA pathway. The relevant competitive group includes major U.S. and international generic manufacturers that have filed or may file Paragraph IV certifications against listed patents.
A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed. If the brand holder sues within the statutory period, FDA approval may be stayed for up to 30 months, subject to litigation developments and statutory exceptions.[4]
Auryxia’s generic-entry risk is higher than it was during the product’s initial commercial period because:
- NCE exclusivity has expired.
- The product is an oral small molecule rather than a biologic.
- Ferric citrate tablets are technically reproducible.
- A mature dialysis market creates an attractive generic volume opportunity.
- Generic applicants can target the phosphate-binder indication while excluding patented anemia uses from the label.
Publicly reported litigation and settlement terms should be checked against current federal court dockets and FDA records before making a launch forecast. Settlement agreements can establish a licensed entry date materially earlier than the latest patent expiration.
What is the Orange Book status of Auryxia?
Auryxia is an FDA-approved prescription drug listed in the Orange Book. The Orange Book identifies patents submitted by the reference-product sponsor and provides the basis for ANDA patent certifications.[3]
The strategic importance of the listing is greater than the number of patents alone suggests. A patent covering the product’s composition can create a broad barrier. A method-of-use patent may be easier to avoid but can still delay or complicate launch. Formulation claims may protect a particular tablet architecture without blocking all ferric citrate products.
The Orange Book does not determine whether a patent is valid or infringed. Those questions are resolved through litigation, settlement, or generic applicant decisions.
How strong is the ferric citrate patent estate?
The estate is moderate rather than dominant.
Strengths include:
- Multiple claim categories developed around composition, formulation, and clinical use.
- A product with two FDA-approved indications.
- A commercial market where payer and physician behavior can delay substitution beyond the legal launch date.
- Clinical differentiation through iron delivery.
Weaknesses include:
- Expired NCE exclusivity.
- Small-molecule chemistry accessible to generic manufacturers.
- Potential for indication carve-outs.
- A mature product with substantial prior-art exposure.
- Competition from inexpensive calcium-based binders and established sevelamer products.
The estate can delay generic competition, but it is unlikely to support indefinite exclusivity.
What generic launch scenarios exist for ferric citrate?
Three launch scenarios are commercially plausible:
Authorized or settlement-based entry
A generic sponsor launches under a license before the last asserted patent expires. This produces controlled erosion, often with the brand retaining a portion of the market through contracts, service programs, and physician loyalty.
First-filer launch
A Paragraph IV first filer obtains 180-day generic exclusivity, creating a period of limited competition. A first filer can generate rapid price erosion while allowing the brand to retain higher-value patients.
Multiple-generic entry
Several manufacturers enter after patent barriers fall or litigation resolves. This is the most damaging scenario for Auryxia revenue. Net price declines accelerate, formulary conversion increases, and the product becomes a lower-margin commodity.
For planning purposes, the commercial risk is less about a single patent expiration date than about the timing of the first credible ANDA launch.
How does ferric citrate affect Akebia’s financial trajectory?
Auryxia has been Akebia’s principal commercial revenue source. It provides recurring cash flow but also exposes the company to concentration risk. The product’s revenue base supports operations, yet its long-term growth ceiling is constrained by the size of the CKD phosphate-binder market and impending generic pressure.
Akebia’s strategic response has been to use Auryxia cash flow and commercial infrastructure while developing Vafseo, an oral treatment for anemia associated with chronic kidney disease. Vafseo was approved by the FDA in March 2024, giving Akebia a potential second commercial platform.[5]
The financial trajectory can be summarized as follows:
| Period |
Expected business effect |
| Near term |
Auryxia remains the main recurring revenue contributor |
| Intermediate term |
Revenue growth depends on pricing, patient retention, and Vafseo uptake |
| Generic-entry period |
Auryxia revenue and gross margin face rapid erosion |
| Longer term |
Akebia’s value shifts toward Vafseo, licensing, and international opportunities |
Auryxia is therefore a cash-generating asset but not a durable growth engine on its own.
What licensing deals and geographic markets matter?
Keryx and Akebia built the Auryxia franchise primarily around the United States. International ferric citrate activity has been more significant in Japan, where ferric citrate hydrate is marketed as Riona by Japan Tobacco and Torii Pharmaceutical.
Geographic value differs by market:
- United States: Largest strategic value for Auryxia and the main source of Akebia product revenue.
- Japan: Established ferric citrate market with local commercialization and reimbursement dynamics.
- Europe: More limited commercial relevance for Auryxia because market access, naming, and product approvals differ.
- Emerging markets: Potential volume opportunity, but generally lower pricing and greater generic competition.
Manufacturing barriers are modest. Ferric citrate tablets do not require biologic manufacturing, sterile fill-finish, or complex device technology. The principal technical barriers are control of iron content, chemical stability, dissolution, impurities, tablet performance, and bioequivalence.
What is the investment outlook for ferric citrate?
Ferric citrate should be valued as a mature specialty product with differentiated clinical utility, not as a high-growth platform.
The positive case depends on:
- Continued physician preference for combined phosphate binding and iron replacement.
- Stable reimbursement.
- Delayed generic entry.
- Effective retention of dialysis-center and nephrology accounts.
- Successful use of Auryxia cash flow to support Vafseo commercialization.
The negative case involves:
- Early Paragraph IV settlement or successful generic litigation.
- Broad formulary substitution.
- Lower reimbursement for oral phosphate binders.
- Weak Vafseo uptake.
- Rising commercial costs to retain Auryxia volume.
Revenue exposure is concentrated. Auryxia erosion would affect Akebia’s operating model disproportionately because the product has historically supplied a large share of recurring commercial revenue.
Key Takeaways
- Ferric citrate is commercially established but mature.
- Auryxia is the principal U.S. ferric citrate product and Akebia’s historical revenue anchor.
- Auryxia revenue increased from about $168 million in 2022 to approximately $178 million in 2023.
- The product benefits from two CKD-related indications but faces sevelamer, sucroferric oxyhydroxide, calcium acetate, and generic competition.
- NCE exclusivity has expired; remaining protection depends on listed patents, method-of-use claims, ANDA litigation, and settlements.
- Generic launch timing is the central value driver for Auryxia.
- Akebia’s long-term financial trajectory depends increasingly on Vafseo offsetting eventual Auryxia erosion.
- Ferric citrate manufacturing is technically accessible to generic companies, making patent and regulatory protection more important than production complexity.
FAQs
Is ferric citrate the same as ferric pyrophosphate citrate?
No. Ferric citrate is the active ingredient in Auryxia and Riona. Ferric pyrophosphate citrate is a different iron compound used in products such as Triferic.
Is Auryxia an iron supplement?
Auryxia can increase iron stores while binding phosphate, but it is approved for specific chronic kidney disease indications. It is not a general over-the-counter iron supplement.
Can generic ferric citrate be substituted automatically for Auryxia?
Automatic substitution depends on FDA approval, state pharmacy law, payer policy, and whether the generic carries the same approved indication. A product with a carved-out label may create substitution limitations.
Does ferric citrate compete with Vafseo?
The products address overlapping CKD-anemia populations but have different mechanisms. Ferric citrate provides iron and phosphate binding. Vafseo is a hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates endogenous erythropoietin biology.
What would cause the fastest decline in Auryxia revenue?
Multiple-generic entry would likely cause the fastest decline through price reductions, formulary substitution, and loss of pharmacy volume. A single licensed entrant would generally create a slower erosion pattern.
References
-
Akebia Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2014, 2020). Auryxia (ferric citrate) prescribing information and approval history. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Patent certifications and 30-month stays. FDA.
-
U.S. Food and Drug Administration. (2024). FDA approves Vafseo for anemia due to chronic kidney disease in adults on dialysis. FDA.
